key: cord-0959652-oewh3neo
authors: Parker, William A.E.; Storey, Robert F.
title: Platelets and the Endothelium: Active Participants in Severe COVID-19 Infection
date: 2021-03-22
journal: JACC Basic Transl Sci
DOI: 10.1016/j.jacbts.2021.01.009
sha: 8573b2c640388e634d320043bbf33188a12630df
doc_id: 959652
cord_uid: oewh3neo

[Figure: see text]

ophysiology, in terms of the infection itself and the host response. Identifying prominent actors in these processes can help find candidate treatments.

It is now established that severe COVID-19 is associated with significant increases in a range of cytokines, including interleukin-6 (IL-6) (1) . It is also clear that microthrombosis and macrothrombosis contribute significantly as pathological mechanisms.

This can manifest as, for example, microvascular dysfunction, pulmonary emboli, or disseminated intravascular coagulation, and an increased risk of atherothrombotic events, such as acute myocardial infarction and ischemic stroke. Furthermore, a strong association between pre-existing cardiovascular dis- Four main processes of particular significance are identified. First, IL-6 seems to be a key cytokine driving platelet hyperreactivity in COVID-19 infection. Although in this study the mechanism for this observation was not fully determined, recent reports have suggested that IL-6 signaling may stimulate platelets via interaction with the platelet collagen receptor glycoprotein VI (3) . Furthermore, a monoclonal antibody against IL-6, tocilizumab, seemed to abrogate these effects, and there is growing evidence this agent may improve clinical outcomes.

Second, platelet-derived microvesicles containing tissue factor seem critical. Tissue factor activates factor VII and therefore the extrinsic pathway of the coagulation cascade, resulting in generation of thrombin that cleaves soluble fibrinogen to insoluble fibrin and activates platelets via protease-associated receptors 1 and 4 (4) . In this study, prophylactic or therapeutic levels of low-molecular-weight heparin were unable to adequately suppress thrombin 

Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment

Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients

Physical proximity and functional cooperation of glycoprotein 130 and glycoprotein VI in platelet membrane lipid rafts

Antithrombotic therapy for patients with chronic coronary syndromes

Aspirin after PCI: in the twilight of its years?

KEY WORDS COVID-19, endothelium, inflammation, platelets